HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Day, C P Search for Related Content PubMed PubMed Citation Articles by Day, C P

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

Correspondence to:
Correspondence to:
C P Day, Centre for Liver Research, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK;
c.p.day{at}ncl.ac.uk

Although non-alcoholic steatohepatitis (NASH) was considered relatively uncommon prior to the middle of the last decade, over the past three years there has been an explosion of studies on various aspects of NASH with one study reporting that after hepatitis C, NASH was the most common diagnosis in patients presenting largely with persistent abnormalities of liver function tests. The field of NASH has come a long way in a relatively short space of time. This article considers advances in knowledge that have arisen as a result of these studies and highlights areas for further work.

Keywords: non-alcoholic steatohepatitis; non-insulin dependent diabetes mellitus; fatty liver disease

Abbreviations: ALT, alanine transaminase; AST aspartate transaminase; BMI, body mass index; FFA, free fatty acids; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NIDDM, non-insulin dependent diabetes mellitus; ROS, reactive oxygen species

This article has been cited by other articles:

				S. Saadeh Nonalcoholic Fatty Liver Disease and Obesity Nutr Clin Pract, February 1, 2007; 22(1): 1 - 10. [Abstract] [Full Text] [PDF]

				H. K. Hussain, T. L. Chenevert, F. J. Londy, V. Gulani, S. D. Swanson, B. J. McKenna, H. D. Appelman, S. Adusumilli, J. K. Greenson, and H. S. Conjeevaram Hepatic Fat Fraction: MR Imaging for Quantitative Measurement and Display--Early Experience Radiology, December 1, 2005; 237(3): 1048 - 1055. [Abstract] [Full Text] [PDF]

				S Dam-Larsen, M Franzmann, I B Andersen, P Christoffersen, L B Jensen, T I A Sorensen, U Becker, and F Bendtsen Long term prognosis of fatty liver: risk of chronic liver disease and death Gut, May 1, 2004; 53(5): 750 - 755. [Abstract] [Full Text] [PDF]

				J. P Iredale Cirrhosis: new research provides a basis for rational and targeted treatments BMJ, July 17, 2003; 327(7407): 143 - 147. [Full Text] [PDF]

				A McNair and C P Day Non-alcoholic steatohepatitis (NASH): why biopsy? Gut, December 1, 2002; 51(6): 898 - 899. [Full Text] [PDF]